Sustaining Income Throughout Retirement

February 1, 2018 admin Investor Education, Personal Finance Comments Off

Retirement Income Strategies

Diggdel.icio.usFacebookRedditStumbleUponTechnorati

Retirement

Nightfood Ice Cream (OTC: NGTF) Scores Two Major National Media Hits: CEO Interviewed on Yahoo Finance PM, and a Feature on Today.com

March 21, 2019 Comments Off on Nightfood Ice Cream (OTC: NGTF) Scores Two Major National Media Hits: CEO Interviewed on Yahoo Finance PM, and a Feature on Today.com
CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

March 21, 2019 Comments Off on CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV
Medicine Man Technologies, Inc., (OTC: MDCL) to Present at Sidoti & Company,Spring 2019 Conference

March 21, 2019 Comments Off on Medicine Man Technologies, Inc., (OTC: MDCL) to Present at Sidoti & Company,Spring 2019 Conference
CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

March 12, 2019 Comments Off on CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)
Nightfood Ice Cream (OTC: NGTF) Expanding Distribution to Sixteen States; Second Production Run This Week, Initial Feedback is Strong

March 11, 2019 Comments Off on Nightfood Ice Cream (OTC: NGTF) Expanding Distribution to Sixteen States; Second Production Run This Week, Initial Feedback is Strong
FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

March 7, 2019 Comments Off on FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)